Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800379 | 1.00 | EPHX1 (0.43) | EPHX1SMN1; SMN2GAAPOLBHTT | |
| Hydrochloric Acid SCHEMBL2146244 | 0.98 | EPHX1 (0.42) | EPHX1SMN1; SMN2GAAPOLBHTT | |
| SCHEMBL15322998 | 0.88 | EPHX1 (0.50) | EPHX1SMN1; SMN2BCHEPSEN1PSEN2 | |
| SCHEMBL15800381 | 0.80 | ALDH1A1 (0.34) | SMN1; SMN2GAAPOLB | |
| SCHEMBL7526914 | 0.80 | ALDH1A1 (0.34) | SMN1; SMN2GAAPOLB | |
| Trifluoroacetic Acid SCHEMBL6506374 | 0.77 | EPHX1 (0.41) | EPHX1BCHE | |
| SCHEMBL13737158 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL28258938 | 0.76 | EPHX1 (0.40) | EPHX1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20594697 | 0.75 | EPHX1 (0.41) | EPHX1SMN1; SMN2GAA | |
| SCHEMBL20594444 | 0.75 | EPHX1 (0.41) | EPHX1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311860-A | For treating or preventing the Xanthone derivative of hepatitis type B virus disease | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | claimed |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3759098-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | Genentech, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| CN-110072855-A | Therapeutic compound and its application method | 基因泰克公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-109311860-A | For treating or preventing the Xanthone derivative of hepatitis type B virus disease | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-102459272-A | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use | GENENTECH INC | 2012-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | CYP1B1, CYP1A1, PAH | EPHX1 483/4885SMN1; SMN2 1451/4885GAA 585/4885 |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | KAT2B, KAT2A, KAT6A | EPHX1 3249/4885SMN1; SMN2 2222/4885GAA 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.